Literature DB >> 3549428

Inhibition of enkephalinase activity attenuates naloxone-precipitated withdrawal symptoms.

J Haffmans, M R Dzoljic.   

Abstract

In this study we examined the effects of the enkephalinase inhibitor, thiorphan, on the naloxone-precipitated withdrawal syndrome in chronic morphine dependent rats. Intracerebroventricular administration of thiorphan (40 micrograms/2 microliter) in morphine dependent rats, inhibited the severity of the naloxone-precipitated abstinential syndrome. Administration of thiorphan (20 micrograms/0.5 microliter) in the periaqueductal grey matter of morphine dependent rats, in addition to explosive motor behaviour and ipsilateral rotation, also significantly suppressed most of the naloxone-precipitated withdrawal symptoms. It is suggested that a decreased biotransformation of endogenous opioid peptides might replace the relative shortage of morphine during withdrawal in opiate addicted subjects and attenuate the abstinence symptoms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549428     DOI: 10.1016/0306-3623(87)90179-0

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  7 in total

1.  Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.

Authors:  R Maldonado; M C Fournié-Zaluski; B P Roques
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

2.  Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: a microdialysis study.

Authors:  Magdalena Mas Nieto; Jodie Wilson; Annie Cupo; Bernard P Roques; Florence Noble
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

3.  Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.

Authors:  F Ruiz; M C Fournié-Zaluski; B P Roques; R Maldonado
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

4.  Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.

Authors:  S J Livingston; R D Sewell; K F Rooney; H J Smith
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Hyperglycemic suppression of morphine withdrawal signs in the rat.

Authors:  H C Akunne; K F Soliman
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.

Authors:  R Maldonado; O Valverde; B Ducos; A G Blommaert; M C Fournie-Zaluski; B P Roques
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

7.  Acute morphine alters GABAergic transmission in the central amygdala during naloxone-precipitated morphine withdrawal: role of cyclic AMP.

Authors:  Michal Bajo; Samuel G Madamba; Marisa Roberto; George R Siggins
Journal:  Front Integr Neurosci       Date:  2014-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.